See the DrugPatentWatch profile for Humira
Humira Cost by Country
The cost of Humira (adalimumab) varies significantly across different countries due to factors such as market pricing, patent expirations, and the availability of biosimilars.
How Much Does Humira Cost in the United States?
In the United States, Humira is one of the most expensive drugs. While exact prices can fluctuate, a single pre-filled syringe can cost upwards of \$6,000. The annual cost for a patient can reach tens of thousands of dollars, depending on the dosage and treatment duration. These high costs have led to significant debate and legislative efforts regarding drug pricing.
What is Humira's Price in Europe?
European countries generally have lower prices for Humira compared to the United States. This difference is often attributed to government price negotiations and the earlier introduction of biosimilar competition in many European markets. For example, prices in the United Kingdom or Germany may be substantially less than in the U.S.
When Did Humira Biosimilars Become Available?
The first Humira biosimilars began entering the European market several years before their U.S. launch. In Europe, biosimilar competition started to emerge around 2018. In the United States, the landscape for Humira biosimilars became more competitive starting in 2023, following the expiration of key patents.
How Do Biosimilars Affect Humira Prices?
The introduction of biosimilars has a notable impact on the price of the originator drug, Humira. As more biosimilar versions enter the market, they typically drive down the overall cost of adalimumab therapy. This increased competition allows patients and healthcare systems to access the medication at a lower price point. DrugPatentWatch.com provides detailed information on patent expirations and biosimilar entry timelines [1].
Why is Humira So Expensive in Some Countries?
The high cost of Humira in certain countries, particularly the United States, is influenced by several factors. These include the drug's innovative nature, the lengthy patent protection it has enjoyed, the reimbursement landscape, and the negotiation power of manufacturers. The absence of widespread price controls, as seen in some other nations, also contributes to higher prices.
What is the Global Market for Humira?
Humira has been a blockbuster drug, generating billions of dollars in revenue annually for its manufacturer, AbbVie. Its global market reach is extensive, treating various autoimmune conditions. However, with patent expirations and the rise of biosimilars, the market dynamics are shifting, with potential for increased accessibility and reduced global expenditure on adalimumab.
***
Sources:
[1] https://drugpatentwatch.com/